Resveratrol 2018, the 5th International Conference on Resveratrol and Health, will be held this year in Xi’an, China on the 18th to 20th October. This is the leading biennial event for those interested in and working on the supporting science behind resveratrol. The conference aims to collate and disseminate the latest knowledge on the biological effects of resveratrol, promote evidenced-based recommendations on its use in humans, as well as identify important areas for further research.
The event is expected to attract well over 100 scientists from around the globe and will comprise over 25 talks together with poster sessions. Evolva is delighted that three independent research groups using Evolva’s Veri-te™ resveratrol products will present at the meeting.
Peter Howe, Ph.D., Emeritus Professor of Clinical Nutrition at the University of Newcastle, Australia, will provide preliminary results on the ongoing RESHAW (Resveratrol Supporting Healthy Ageing in Women) clinical trial. This 2 year, randomized cross-over clinical trial is the longest and largest (140 participants) resveratrol supplement trial to be undertaken in postmenopausal women and will examine the outcomes of cognitive performance, cerebrovascular responsiveness, bone mineral density and muscle mass. In addition, Professor Howe’s research will inform on numerous additional parameters including adiposity, mood, quality of life (including sleep, pain and menopausal symptoms), physical functions and cardiometabolic markers. This is a very important and exciting trial for the study of resveratrol.
Dr. Scott Boyer, founder and scientific advisor at Nutrinovate AB, Sweden, will present results on the plasma exposure of resveratrol (bioavailability) as delivered to the lining of the mouth from Nutrinovate’s award winning Reserol product, which uses their Functional Film Technology™ with Veri-te™ resveratrol. The uptake of resveratrol via the oral mucosa is radically different from the absorption of capsules, tablets, liquid shots and other orally dissolvable formulations absorbed via the gut. Nutrinovate is the winner of the ‘Editor’s Award for Innovation’ category at the NutraIngredients Awards 2018 and ‘Editor’s Award for Functional Food Innovation’ at the NutraIngredients Asia Award 2018 in Singapore.
Karen Brown, Ph.D., Professor of Translational Cancer Research at the University of Leicester, UK, will discuss the use of resveratrol in treatment of colorectal cancer. In addition to the role of resveratrol as a dietary supplement, there is increasing interest in its use as an adjunct to drug therapies for several serious conditions. Cancer is a prominent area for current resveratrol research and Professor Brown will share results demonstrating how resveratrol may affect the development of many different colorectal cancer subtypes and supporting data that suggests the use of resveratrol in colorectal adenoma prevention trials.
The conference promises to be an exciting meeting, with many areas of resveratrol research being presented. Topics covered at Resveratrol 2018 range from the effects on resveratrol on the gut microbiota, other forms of cancer, diseases and several other health conditions including nonalcoholic fatty liver disease, colitis, heart failure, severe shock and inflammation.
With its continued interest in and commitment to the understanding of the science behind resveratrol, Evolva is pleased to be a co-sponsor of this event, as it has been in previous years, and looks forward to hearing about the latest studies and results from the resveratrol research community.